LAX.SH
IND SWIFT LABORATORIES LT·PHARMACEUTICALS 70.24·Pharmaceuticals & Biotechnology Companies
Price
329.59
-1.18%52W Range
Market Cap
₹2,862.05 Cr
Traded: ₹12.08 Cr (0.42%) 0.0x
Free Float: ₹1,134.80 Cr (1.06% of FF traded)
Volume · 60D trend
3.67 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +0.0% | -6.0% | -19.0% | -- | +14.0% | Stable |
| Profit | +12.0% | +78.0% | -7.0% | -- | +2695.0% | Stable |
| Return | +13.0% | +10.0% | +24.0% | +70.0% | -- | Accelerating |
| ROE | +3.0% | +6.0% | +7.0% | -- | -- | Accelerating |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 191 | 170 | 151 | 153 | 153 | 138 | 129 | 12 | 33 | 529 | 288 | 290 | 310 | 304 | 313 | 310 |
| Expenses | 158 | 149 | 147 | 151 | 149 | 147 | 135 | 24 | 43 | 437 | 236 | 224 | 250 | 241 | 259 | 251 |
| Operating Profit | 33 | 21 | 4 | 1 | 4 | -9 | -7 | -12 | -10 | 91 | 52 | 66 | 60 | 64 | 54 | 59 |
| OPM % | 17.0% | 12.0% | 2.8% | 1.0% | 2.4% | -7.0% | -5.0% | -99.0% | -29.0% | 17.0% | 18.0% | 23.0% | 19.0% | 21.0% | 17.2% | 18.9% |
| Other Income | 7 | -3 | 22 | 18 | 15 | 220 | 16 | 13 | 11 | 458 | 7 | 7 | 6 | -16 | 8 | 8 |
| Interest | 1 | -2 | 1 | 2 | 1 | -27 | 10 | 0 | 0 | 3 | 21 | 21 | 20 | 22 | 22 | 24 |
| Depreciation | 8 | 8 | 9 | 7 | 7 | 7 | 6 | 0 | 0 | 20 | 14 | 13 | 14 | 9 | 15 | 16 |
| Profit Before Tax | 33 | 12 | 16 | 10 | 10 | 230 | -7 | 1 | 1 | 527 | 24 | 39 | 32 | 16 | 24 | 26 |
| Tax % | 25.0% | -26.0% | 42.0% | 22.0% | 17.0% | 4.0% | -16.0% | 31.0% | -3.0% | 6.0% | 19.0% | 18.0% | 45.0% | 255.0% | -13.4% | 2.2% |
| Net Profit | 25 | 15 | 10 | 8 | 9 | 222 | -5 | 0 | 1 | 494 | 19 | 32 | 17 | -25 | 28 | 25 |
| Exceptional Items | -- | -5 | -6 | 0 | 0 | 216 | -1 | 0 | 0 | 387 | 0 | 0 | 0 | -27 | 0 | 0 |
| EPS (Rs) | 2.8 | 1.7 | 1.2 | 1.0 | 1.4 | 36.7 | -0.9 | 0.1 | 0.2 | 83.5 | 3.3 | 5.4 | 2.9 | -4.3 | 4.7 | 4.3 |
| Sales Growth (YoY) | -- | 22.8% | 17.1% | 1176.3% | 360.4% | -73.8% | -55.2% | -95.9% | -89.3% | 73.7% | -8.1% | -6.6% | 10.8% | -0.8% | -- | -- |
| Sales Growth (QoQ) | -- | 12.6% | -1.3% | 0.0% | 10.9% | 7.0% | 975.0% | -63.6% | -93.8% | 83.7% | -0.7% | -6.5% | 2.0% | -2.8% | 0.8% | -- |
| OP Growth (YoY) | 725.0% | 333.3% | 157.1% | 108.3% | 140.0% | -109.9% | -113.5% | -118.2% | -116.7% | 42.2% | -3.3% | 12.3% | -- | -- | -- | -- |
| OP Growth (QoQ) | 57.1% | 425.0% | 300.0% | -75.0% | 144.4% | -28.6% | 41.7% | -20.0% | -111.0% | 75.0% | -21.2% | 10.0% | -6.3% | 19.0% | -8.5% | -- |
| Profit Growth (YoY) | -- | 9.3% | 371.9% | 1848.8% | 833.0% | -87.3% | -124.5% | -98.7% | -94.5% | 450.7% | -29.4% | 24.9% | -13.3% | 35.5% | 72.0% | 4.0% |
| EPS Growth (YoY) | -- | -95.3% | 225.8% | 1300.0% | 806.3% | -56.1% | -128.3% | -98.7% | -94.5% | 2065.9% | -29.3% | 24.9% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 48.7% | 19.4% | -32.4% | -96.0% | 4043.0% | -1428.6% | -56.3% | -99.8% | 2439.5% | -38.6% | 83.6% | 168.7% | -191.4% | 8.4% | -- |
| OP Margin | -- | 12.3% | 2.6% | 0.7% | 2.6% | -6.5% | -5.4% | -100.0% | -30.3% | 17.2% | 18.1% | 22.8% | 19.4% | 21.1% | 17.2% | 18.9% |
| Net Margin | -- | 8.8% | 6.6% | 5.2% | 5.9% | 160.9% | -3.9% | 0.0% | 3.0% | 93.4% | 6.6% | 11.0% | 5.5% | -8.2% | 8.8% | 8.2% |
| Material Cost % | -- | 36.2% | 46.6% | 50.9% | 47.9% | 41.7% | 47.9% | 69.5% | 82.3% | 50.5% | 54.1% | 49.9% | 52.3% | 53.4% | 58.4% | 54.0% |
| Employee Cost % | -- | 21.9% | 21.2% | 23.8% | 21.3% | 22.7% | 23.0% | 48.5% | 18.4% | 11.7% | 12.9% | 12.9% | 12.6% | 11.7% | 10.6% | 11.0% |
| P/S | 4.30 | 3.29 | 1.97 | 2.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 48.97 | 44.43 | 3.35 | 3.81 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.07 | 1.49 | 0.89 | 0.91 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Please find enclosed Transcript of Earning Call held on August 17, 2026.
Please find enclosed press release titled as Ind-Swift to make Jammu facility EUGMP and PICS Compliant targets additional revenue of 100 crores from 2029-30 onwards .
Audio recording of earning conference call held on 17.08.2026 on un-audited financial results for the quarter ended 30.06.2026.
Please find attached intimation regarding the investor presentation on un-audited financial results for the quarter ended June, 30 2026.
Please find enclosed Schedule of Analyst / Investor Meet will be held on Monday, 17th August, 2026, at 03.00 P.M. IST in respect of financial results of the Company for the quarter ended ....
Please find enclosed report of the Monitoring Agency for the quarter ended June 30, 2026.
Please refer attached pdf .
please refer attached pdf.
Please find enclosed Statement of NIL Deviation for the Quarter ended June 30, 2026
Please find enclosed outcome of the Board Meeting Dated August 10, 2026
Please refer attached pdf
Please find enclosed voting results along with scrutinizer''s report
Please find attached proceedings of EGM which was held today i.e., on 5th August, 2026
Please refer attached pdf.
Newspaper Publication regarding dispatch of Notice calling Extra Ordinary General Meeting schedule to be held on 5th August, 2026.
Please refer attached pdf.
Please refer attached pdf.
Please refer attached pdf
Ind-Swift Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/07/2026 ,inter alia, to consider and approve raising of funds by ....
Please refer attached pdf.
Please refer attached pdf.
Please refer attached pdf.
Please refer attached pdf.
Please refer enclosed pdf.
Please refer attached pdf.
Intimation of allotment of 1,25,000 equity shares pursuant to ESOP, 2014.
Please refer attached pdf.
Please refer attached pdf.
Audited Financial results for the Quarter and Financial year ended 31st March 2026
Ind-Swift Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve and take on record Standalone ....
Please find enclosed report of the Monitoring Agency for the quarter ended March 31, 2026.
Please find attached Scrutinizer''s Report along with Voting Results for the resolutions passed through postal ballot on 30.04.2026.
Please refer attached disclosure under SEBI (SAST) Regulations, 2011 received from HCP Investments
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HCP Investments
Please refer attached pdf.
The Exchange has sought clarification from Ind-Swift Laboratories Ltd on April 9, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Intimation of receipt of Arbitration Award
Newspaper clippings- Special Window for re-lodgement of transfer requests of physical shares and dematerialisation
Please refer attached pdf.
Intimation of allotment of 1,25,000 shares pursuant to ESOP 2014
Please refer attached pdf
Intimation regarding closure of Trading Window w.e.f. 1st April, 2026.
Please find attached Notice of Postal Ballot
Outcome of Board Meeting held on March 27, 2026
Please refer attached pdf.
Please refer attached pdf.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Essix Biosciences Ltd & Others
Please find attached intimation received from M/s. Essix Biosciences Limited
Please refer attached pdf.
Intimation of allotment of equity shares upon conversion of warrants
Annual Reports
14Credit Ratings
6